FAP and fibrosarcoma: The high efficacy of combining anti-FAP CAR-T cells with other immunotherapies (e.g., checkpoint inhibition) was proven by Gulati et al., who achieved transiently stable disease in a humanized fibrosarcoma mouse model treated with anti-FAP (F19 mAb) CAR-T cells in combination with a PD-1-blocking mAb [148].